Click on image to view larger version.

Figure 4 Rates of all-cause mortality (D) or myocardial infarction (MI) through 30 days in the heparin alone and tirofiban plus heparin treatment groups in Platelet Receptor inhibition for Ischemic Syndrome Management in Patients Limited to very Unstable Signs and Symptoms (PRISM-PLUS), with patients stratified by Thrombolysis In Myocardial Infarction (TIMI) trial risk score.